Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06379490
Other study ID # CTA no: 2024-510572-20-00
Secondary ID 2024-510572-20-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 23, 2024
Est. completion date September 1, 2025

Study information

Verified date April 2024
Source Nordsjaellands Hospital
Contact Anders K. Nørskov, PhD
Phone 48 29 74 59
Email anders.kehlet.noerskov@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate the feasibility of the lateral infraclavicular plexus brachialis (LIC) block for acute closed reduction of distal radius fractures, the investigators will compare the pain-relieving and muscle-relaxing properties of the LIC block with short- and long-acting local anesthetics in different concentrations but at the same volume. In addition to motor and sensory blockade during repositioning, feasibility will also be assessed by other patient-related and block-related factors, as well as by factors related to the repositioning and plastering procedure.


Recruitment information / eligibility

Status Recruiting
Enrollment 63
Est. completion date September 1, 2025
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients who have given written informed consent to participate in the study after having understood it, as well as: • Having a distal radius fracture requiring closed reduction Exclusion Criteria: Patients who meet one or more of the following criteria will be excluded from participating in the study: - BMI > 40 kg/m2 - Weight < 50 kg - Age < 18 years - American Society of Anesthesiologists (ASA) physical status classification system grade >3 - Allergy to experimental drugs - Patients who cannot cooperate with the examinations or treatment - Patients who do not understand or speak Danish - Patients with peripheral or central neurological disease or nerve damage with neurological effect on the upper extremity, where closed reduction is required

Study Design


Intervention

Drug:
Ropivacaine 0.2% Injectable Solution
30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
Lidocaine epinephrine
30 ml of Lidocaine 1% with 5 µg/ml epinephrine = 300 mg lidocaine + 150 µg epinephrine
Ropivacaine 0.5% Injectable Solution
30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine

Locations

Country Name City State
Denmark Copenhagen University Hospital - North Zealand Hillerød

Sponsors (1)

Lead Sponsor Collaborator
Nordsjaellands Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Degree of sensory and motor blockade Degree of sensory and motor blockade 30 and 45 minutes after block performance.
Sensory blockade assessment:
A 3-point scale is used for cold sensation assessment: 1 point = normal sensation of cold, 2 points = reduced sensation of cold and 3 points = no cold sensation.
A complete sensory blockade is defined as all four nerves obtaining 3 points (no cold sensation).
Motor blockade assessment:
Assessment is done using a 4-point Manual Muscle Testing Scale: 3 points = no difference, movement against resistance is possible, 2 points = a slight difference, movement against slight resistance is possible, 1 point = movement is significantly compromised, 0 point = paralysis.
A complete motor blockade is defined as all four nerves obtaining: 1 point or 0 points.
30 to 45 minutes after block performance
Other Total duration of sensory blockade From the completion of the LIC block until the ending of the sensory blockade.
Duration in hours:minutes.
24 hours after completed block performance
Other Total duration of motor blockade From the completion of the LIC block until the ending of motor blockade.
Duration in hours:minutes.
24 hours after completed block performance
Other Pain intensity before block performance Pain intensity measured before block performance with a numeric rating scale (NRS 0 - 10 (0 = no pain; 10 = worst pain imaginable)) Up to 45 minutes after inclusion interview
Other Time to pain relief/lowest pain intensity Time to pain relief/lowest pain intensity after block performance and before performing the closed reduction
Duration in hours:minutes
Up to 45 minutes after block performance
Other Pain intensity during closed reduction Pain intensity measured during closed reduction with a numeric rating scale (NRS 0 - 10 (0 = no pain; 10 = worst pain imaginable)) Duration of closed reduction (approx. 5 to 10 minutes)
Other Pain intensity during cast application Pain intensity measured during cast application with a numeric rating scale (NRS 0 - 10 (0 = no pain; 10 = worst pain imaginable)) Duration of cast application (approx. 5 to 10 minutes)
Other Time to pain breakthrough after the blockade has ended Time after block performance until pain breakthrough defined as NRS>3 (NRS 0 - 10 (0 = no pain; 10 = worst pain imaginable))
Duration in hours:minutes
Up to 24 hours after block performance
Other Maximum pain intensity after the blockade has ended Pain intensity measured after the blockade has ended with a numeric rating scale (NRS 0 - 10 (0 = no pain; 10 = worst pain imaginable)) Up to 24 hours after block performance
Other Duration of maximum pain intensity after the blockade has ended Time period of maximum pain intensity after the blockade has ended
Duration in hours:minutes
Up to 24 hours after block performance
Other Amount of strong painkillers consumed by patients within 24 hours after closed reduction Amount of strong painkillers consumed by patients within 24 hours after closed reduction will be measured in 24-hour morphine equivalents (milligrams). 24 hours after completed block performance
Other Grading of closed reduction difficulty Grading of closed reduction difficulty measured with a numeric rating scale (NRS 0 - 10 (0 = no difficulty; 10 = very difficult)) Duration of closed reduction (approx. 5 to 10 minutes)
Other Quality of closed reduction evaluated by X-ray imaging Quality of closed reduction evaluated by X-ray imaging using the following radiological criteria:
More than 10 degrees of dorsal angulation of the articular surface of the radial in a side view as compared to perpendicular to the longitudinal axis of the radial
Ulnar variance of more than 2 mm
Articular step-off of more than 2 mm
Incongruity of the distal radioulnar joint
Loss of substance/comminuted fracture of the dorsal cortex
24 hours and 30 days after block performance
Other Attempts used for closed reduction Number of attempts used for closed reduction. One attempt is defined as closed reduction before X-ray control imaging. Up to 4 hours after block application
Other Grading of casting difficulty Grading of casting difficulty measured with a numeric rating scale (NRS 0 - 10 (0 = no difficulty; 10 = very difficult)) Duration of cast application (approx. 5 to 10 minutes
Other The patient's experience of the treatment The patient's experience of the treatment using a numeric rating scale (NRS 0 - 10 (0 = very dissatisfied; 10 = very satisfied)) Up to 24 hours after block performance
Other Occurence of adverse events (AE) and serious adverse events (SAE) Adverse events are defined as any harmful or unwanted events, signs, or symptoms that occur during participation in the study period.
Serious adverse events are defined as events resulting in death, a life-threatening condition, permanent disability, hospital admission, or prolonged hospital admission.
Based on phone interviews and medical records 24 hours and 30 days after the procedure.
24 hours and 30 days after block performance
Primary Block success The incidence of successful blockade 45 minutes after block performance.
The following 4 nerves will be tested: radial, musculocutaneous, ulnar and median nerves.
Sensory blockade assessment:
A 3-point scale is used for cold sensation assessment: 1 point = normal sensation of cold, 2 points = reduced sensation of cold and 3 points = no cold sensation.
A complete sensory blockade is defined as all four nerves obtaining 3 points (no cold sensation).
Motor blockade assessment:
Assessment is done using a 4-point Manual Muscle Testing Scale: 3 points = no difference, the movement against resistance is possible, 2 points = a slight difference, the movement against slight resistance is possible, 1 point = movement is significantly compromised, 0 points = paralysis.
A complete motor blockade is defined as all four nerves obtaining: 1 point or 0 points.
Successful blockade:
• Complete sensory and motor blockade 45 minutes after block performance.
45 minutes after block performance
See also
  Status Clinical Trial Phase
Completed NCT06355817 - Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration N/A
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT04692896 - Effect of Different Concentrations of Lidocaine in Relieving Pain in Wide Awake Hand Surgery Using Tumescence Phase 1
Recruiting NCT06088875 - Nebulization Versus Spray-as-You-Go Airway Topical Anesthesia Using Dexmedetomidine and Lidocaine Mixture During Awake Flexible Fiberoptic Intubation in Temporomandibular Ankylosis N/A
Recruiting NCT04169854 - Pre-emptive Topical Lidocaine 5% Plaster for Prevention of Post-craniotomy Pain Phase 3
Completed NCT04076865 - Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch N/A
Completed NCT02987985 - Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy Phase 3
Recruiting NCT05089526 - Opioid-free Anesthesia in Laparoscopic Cholecystectomies N/A
Recruiting NCT03871478 - Comparing the Efficacy of Local Anesthetics in Mohs Surgery N/A
Recruiting NCT03673163 - Lidocaine Infusion for Pain After Herniotomy N/A
Recruiting NCT03666299 - Lidocaine Infusion for Postthoracotomy Pain Syndrome N/A
Recruiting NCT05158348 - A Comparative Study to Measure the Effect of Nebulized Dexmedetomidine Phase 3
Completed NCT06135688 - Effects of Lidocaine Bolus and Infusion on Bispectral Index Values and Spectrum During Anesthesia Maintenance
Completed NCT04008433 - Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated With Medium-/Long-chain Triglycerides N/A
Recruiting NCT04622904 - Lidocaine and Magnesium and Ketamine in Gynecological Surgery N/A
Recruiting NCT05717361 - Opioid Sparing Anesthesia in Cervical Spine Surgery N/A
Withdrawn NCT04359017 - Systemic Absorption of Lidocaine After Hematoma Block Phase 4
Recruiting NCT04144933 - Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery Phase 3
Recruiting NCT05243940 - Opioid-free Anesthesia in Thyroidectomies N/A
Completed NCT05484687 - Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors N/A